A platform for research: civil engineering, architecture and urbanism
A platform for research: civil engineering, architecture and urbanism
Genome Editing VEGFA Prevents Corneal Neovascularization In Vivo
https://orcid.org/0000-0001-9952-3175
AbstractCorneal neovascularization (CNV) is a common clinical finding seen in a range of eye diseases. Current therapeutic approaches to treat corneal angiogenesis, in which vascular endothelial growth factor (VEGF) A plays a central role, can cause a variety of adverse side effects. The technology of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 can edit VEGFA gene to suppress its expression. CRISPR offers a novel opportunity to treat CNV. This study shows that depletion of VEGFA with a novel CRISPR/Cas9 system inhibits proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs) in vitro. Importantly, subconjunctival injection of this dual AAV‐SpCas9/sgRNA‐VEGFA system is demonstrated which blocks suture‐induced expression of VEGFA, CD31, and α‐smooth muscle actin as well as corneal neovascularization in mice. This study has established a strong foundation for the treatment of corneal neovascularization via a gene editing approach for the first time.
Genome Editing VEGFA Prevents Corneal Neovascularization In Vivo
https://orcid.org/0000-0001-9952-3175
AbstractCorneal neovascularization (CNV) is a common clinical finding seen in a range of eye diseases. Current therapeutic approaches to treat corneal angiogenesis, in which vascular endothelial growth factor (VEGF) A plays a central role, can cause a variety of adverse side effects. The technology of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 can edit VEGFA gene to suppress its expression. CRISPR offers a novel opportunity to treat CNV. This study shows that depletion of VEGFA with a novel CRISPR/Cas9 system inhibits proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs) in vitro. Importantly, subconjunctival injection of this dual AAV‐SpCas9/sgRNA‐VEGFA system is demonstrated which blocks suture‐induced expression of VEGFA, CD31, and α‐smooth muscle actin as well as corneal neovascularization in mice. This study has established a strong foundation for the treatment of corneal neovascularization via a gene editing approach for the first time.
Genome Editing VEGFA Prevents Corneal Neovascularization In Vivo
https://orcid.org/0000-0001-9952-3175
AbstractCorneal neovascularization (CNV) is a common clinical finding seen in a range of eye diseases. Current therapeutic approaches to treat corneal angiogenesis, in which vascular endothelial growth factor (VEGF) A plays a central role, can cause a variety of adverse side effects. The technology of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 can edit VEGFA gene to suppress its expression. CRISPR offers a novel opportunity to treat CNV. This study shows that depletion of VEGFA with a novel CRISPR/Cas9 system inhibits proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs) in vitro. Importantly, subconjunctival injection of this dual AAV‐SpCas9/sgRNA‐VEGFA system is demonstrated which blocks suture‐induced expression of VEGFA, CD31, and α‐smooth muscle actin as well as corneal neovascularization in mice. This study has established a strong foundation for the treatment of corneal neovascularization via a gene editing approach for the first time.
Genome Editing VEGFA Prevents Corneal Neovascularization In Vivo
Advanced Science
Zeng, Zhenhai (author) / Li, Siheng (author) / Ye, Xiuhong (author) / Wang, Yiran (author) / Wang, Qinmei (author) / Chen, Zhongxing (author) / Wang, Ziqian (author) / Zhang, Jun (author) / Wang, Qing (author) / Chen, Lu (author)
Advanced Science ; 11
2024-07-01
Article (Journal)
Electronic Resource
English
Genome Editing VEGFA Prevents Corneal Neovascularization In Vivo (Adv. Sci. 25/2024)
| Wiley | 2024
Genome Editing VEGFA Prevents Corneal Neovascularization In Vivo (Adv. Sci. 25/2024)
| Wiley | 2024